526 – the Role of Tuft Cell Specification and Function in Inflammatory Ileitis
Amrita Banerjee,Charles A. Herring,Alan J. Simmons,Hyeyon Kim,Eliot T. McKinley,Bob Chen,Paige Vega,Qi Liu,Robert J. Coffey,Ken S. Lau
DOI: https://doi.org/10.1053/j.gastro.2019.01.193
IF: 29.4
2019-01-01
Gastroenterology
Abstract:Glucagon-like peptide-2 (GLP-2) is an intestinotrophic hormone produced by intestinal L cells that stimulates proliferation in the intestinal crypt.However, the GLP-2 receptor is not expressed in the crypt but, rather, in subepithelial myofibroblasts that subtend this compartment.Consistent with an indirect mechanism of action of GLP-2, knockout (KO) of insulin-like growth factor-1 (IGF-1) or its intestinal epithelial receptor (IE-IGF-1R) decreases the proliferative effect of GLP-2 in mice.Similarly, administration of a pan-ErbB inhibitor or IE-Erb1 KO decreases GLP-2-induced crypt proliferation, while co-administration of epidermal growth factor (EGF) and GLP-2 in rats and piglets causes an enhanced proliferative effect.Interestingly, it has recently been shown in IEC-6 cells that pre-treatment with EGF before IGF-1 synergistically increases their proliferation.We, therefore, hypothesized that EGF enhances IGF-1-mediated GLP-2-induced proliferation in mice.C57BL/6J mice (n=8-9 per group, males and females) were treated with vehicle or 0.2 mg/g-d h(Gly 2 )GLP-2 (a degradation-resistant human GLP-2 analog); 0.4 mg/g-d murine EGF was given either as a pre-treatment at -3 h and/or as a co-treatment with EGF alone or with the GLP-2, for 11 d (Table 1).Body weight and small intestinal length did not change between the groups.However, small intestinal weight normalized to body weight and to small intestinal length was highest in group 8, the pre+co-EGF plus GLP-2 combination group compared to vehicle (p<0.001).Jejunal crypt-villus height analysis showed that all EGF plus GLP-2 combination treatments (groups 4, 6, 8) were more effective than vehicle, GLP-2 or EGF alone (p<0.05-0.001).Conversely, jejunal EdU uptake assessment demonstrated that GLP-2, but not EGF, induced crypt proliferation.RT-qPCR showed no changes in the expression of either the ligands or their receptors for all test agents.To determine the relationship between EGF-GLP-2 and IGF-1, male and female IE-IGF-1R KO mice (C57Bl/ 6 villin-cre-ER T2+ :IGF-1R fl/fl ) mice and all genetic/tamoxifen controls, were then treated with vehicle or pre+co-EGF, alone or with GLP-2, as above (i.e.groups 1, 2, 7, 8).RT-qPCR on jejunal mucosa confirmed 85% KO of the IE-IGF-1R.Preliminary crypt-villus height results showed that, while the intestinotrophic effects of GLP-2 were blunted in the KO mice, as expected, the KO animals retained the growth effects of pre+coEGF treatment as well as that of pre+co-EGF plus GLP-2.In conclusion, EGF enhances the chronic intestinotrophic effects of GLP-2 through a mechanism other than crypt cell proliferation, although IGF-1R signaling may not be required for EGF-induced proliferation, alone or in combination with GLP-2.These findings have implications with respect to our understanding of the mechanisms of action of both GLP-2 and EGF in the gut.Experiment #1 Treatment Groups